NASDAQ:GLSI Greenwich LifeSciences Q3 2025 Earnings Results & Report $17.77 +1.24 (+7.50%) Closing price 10/12/2026 04:00 PM EasternExtended Trading$17.76 -0.01 (-0.06%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Greenwich LifeSciences met analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$0.30 versus the -$0.30 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 14, 2025TimeBefore Market OpensConference Call7:00 AM ET Greenwich LifeSciences EPS ResultsActual EPS-$0.30Consensus EPS -$0.30Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersGreenwich LifeSciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsGreenwich LifeSciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Greenwich LifeSciences Q3 2025 Earnings FAQ Did Greenwich LifeSciences beat earnings estimates for Q3 2025? Greenwich LifeSciences (NASDAQ:GLSI) reported earnings of -$0.30 per share for Q3 2025, matching the consensus estimate of -$0.30. The report was announced on Friday, November 14, 2025. When is Greenwich LifeSciences' next earnings date? Greenwich LifeSciences' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Greenwich LifeSciences on the company's earnings history page. Greenwich LifeSciences Earnings Headlines3 Clinical-Stage Cancer Stocks With Pristine Balance SheetsSeptember 16, 2026 | finance.yahoo.comGreenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027August 10, 2026 | quiverquant.comQHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027August 10, 2026 | globenewswire.comGreenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer TrialJuly 22, 2026 | quiverquant.comQGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United KingdomJuly 22, 2026 | globenewswire.comSee More Greenwich LifeSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Greenwich LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenwich LifeSciences and other key companies, straight to your email. Email Address About Greenwich LifeSciencesGreenwich LifeSciences (NASDAQ:GLSI) is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to reduce the risk of breast cancer recurrence. The company’s lead product candidate is GLSI-100, an investigational vaccine intended for patients with HER2-positive breast cancer who have completed standard treatment. GLSI-100 combines GP2, a peptide derived from the HER2 protein, with granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-system stimulant. Greenwich LifeSciences is evaluating the therapy in clinical studies, including the Phase III PRESENT trial, which is designed to assess whether GLSI-100 can help prevent recurrence in eligible patients. Greenwich LifeSciences is headquartered in Houston, Texas, and its activities are centered on the development of GLSI-100 rather than the marketing of approved pharmaceutical products. The company was founded by Snehal Patel, who serves as its chief executive officer.View Greenwich LifeSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
